NUH
Singapore
Location status: Recruiting
NCT Number: NCT06816446
The prevalence of myopia in Singapore is among the highest in the world, with 65 percent of our children being myopic by Primary 6, and 83 percent of young adults being myopic. As such, Singapore is often labelled as the "Myopia Capital of the World". By 2050, it is projected that 80 to 90 per cent of all Singaporean adults above 18 years old will be myopic and 15 to 25 percent of these individuals may have high myopia.
High myopia (spherical equivalent refraction ≤ -5 D) puts one at risk of many eye disorders later in life, such as early cataracts, glaucoma and macular degeneration. These complications often cause significant morbidity and may even be sight-threatening. Hence there is an urgent and growing need for synergistic efforts to counter myopia.
The goal of this clinical trial is to test the efficacy of spectacle lenses in controlling the progression of myopia in children (aged 6-12 years) over a period of 2 years. In addition, this trial aims to evaluate the impact of these spectacle lenses on central visual performance and visual comfort.
Therefore, in this randomised, double-masked clinical trial, one hundred and eighty-five (n=185) subjects aged 6-12 years with mild or moderate myopia (< -5D) will be randomised in a 1:1 allocation ratio into three strata defined by age 6-8, 8-10 and 10-12 years to ensure age balance between the two arms (control group - single vision lenses and intervention group - myopia control lenses, gender matched). In the control group, after one year (12 months) of wearing single vision lenses, the children will switch to the myopia control lenses (crossover design).
Interested in participating?
Request Info6 year–12 year
All sexes
Interventional
Not applicable
Singapore
Location status: Recruiting
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The intervention group will wear specially designed lenses that aim to slow the progression of myopia. Follow-up visits will take place at regular intervals.
The control group will wear single vision lenses for one year. They will then switch to the myopia control lens for a further year. Follow-up visits will take place at regular intervals.
Time frame: 2 years
Change in spherical equivalent refraction
Time frame: 2 years
Change in axial length from baseline
Time frame: 2 years
Change in peripheral refraction from baseline
Time frame: 2 years
Change of choroidal thickness from baseline
Time frame: 1 year
Difference in central visual acuity between single vision lenses and myopia control lenses
Time frame: 1 year
Difference in contrast sensitivity between single vision lenses and myopia control lenses
Time frame: 1 year
Difference in visual comfort between single vision lenses and myopia control lenses
Time frame: 2 years
Impact of light exposure characteristics on myopia progression
Contact information is provided by the study sponsor or research team.
Rodenstock GmbH
Industry
Testing the Efficacy of Rodenstock Spectacle Lenses in Myopia Progression: a Two Year Clinical Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07316998
Eye Diseases, Myopia
Paris, France
View Trial DetailsNCT07567040
Eye Diseases, Myopia
Birmingham, Alabama, United States
View Trial DetailsNCT07698977
Eye Diseases, Myopia
Budapest, Hungary
View Trial DetailsNCT07512102
Eye Diseases, Myopia
Guangzhou, Guangdong, China
View Trial Details